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dramatically	extended	healthspan	and	 trippled	 life	 span.	Here,	we	show	that	 rapa-








not	mediate	 the	beneficial	 effects	 of	DR	 in	progeroid	mice,	 revealing	 that	DR	and	
rapamycin strongly differ in their modes of action.
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1  |  INTRODUC TION
Caloric	 or	 dietary	 restriction	 (CR/DR;	 reduced	 total	 dietary	 in-
take	 without	 malnutrition)	 is	 the	 best	 documented	 intervention	
that	 compresses	 morbidity	 and	 extends	 life	 span	 (Fontana	 et	 al.,	
2010;	 Speakman	&	Mitchell,	 2011).	 Restricting	 diet	 under	 labora-
tory conditions has been shown to promote health and delay aging 
in	 numerous	 species	 ranging	 from	 yeast	 to	 non-human	 primates,	
suggesting an evolutionary well-conserved mechanism underlying 





would	 react	 to	 an	 extended	 period	 of	DR	 in	 terms	 of	 compliance	
and	potential	side	effects	of	DR	(Dirks	&	Leeuwenburgh,	2006;	Most	
et	al.,	2017).
Despite	 decade-long	 research,	 the	 mechanisms	 underlying	
DR	are	 still	 poorly	 understood,	 although	energy	expenditure	with	
suppression	of	nutrient-sensing	pathways	via	GH/IGF1	and	mTOR	
signaling has been reported as two primary regulatory pathways 
in	 the	 healthspan	 and	 life	 span	 extension	 by	 DR	 (Barzilai	 et	 al.,	






feeling	 (Ingram	&	Roth,	2015).	 To	date,	 the	most	 robust	 interven-
tion,	besides	DR,	 is	rapamycin	 (Blagosklonny,	2019;	Fontana	et	al.,	




has consistently been found to extend life span in numerous spe-
cies	(Barbet	et	al.,	1996;	Garratt	et	al.,	2016;	Kaeberlein	et	al.,	2005;	





counterintuitively—severely	 growth-attenuated,	 progeroid	 DNA	
repair	mutant	mice	benefit	extraordinarily	from	DR:	Whereas	30%	
DR	 in	wild-type	 (WT)	mice	 leads	on	average	 to	a	30%	 increase	 in	
life	 span	 (Weindruch	 &	 Sohal,	 1997),	 the	 increase	 in	 life	 span	 of	
short-lived Ercc1∆/−	progeroid	mice	was	more	than	2-fold	(Vermeij,	
Dollé,	et	al.,	2016).	As	Ercc1∆/− mutant mice are defective in multiple 
DNA	repair	processes	including	transcription-coupled	repair	(TCR),	
global-genome	nucleotide	excision	repair	(GG-NER),	and	interstrand	
crosslink	 repair,	 several	 types	 of	 endogenous	DNA	 lesions,	which	






is reduced to about 4–6 months during which they develop wide-
spread multimorbidity also seen in normal mouse and human aging 
(Dollé	et	al.,	2011;	Vermeij	et	al.,	2016).	Applying	DR	to	these	and	
other	 progeroid	 DNA	 repair	 mutant	 mice,	 dramatically	 extended	
life	span,	improved	overall	health	and	delayed	numerous	aspects	of	
aging,	 including	 neurodegeneration.	More	 importantly,	 it	 reduced	
the	endogenous	DNA	damage	load	and	transcription	stress,	lower-
ing	one	of	the	causal	hallmarks	of	aging	(Vermeij,	Dollé,	et	al.,	2016;	









body weight Ercc1∆/− mice eat 1.3 times more than their repair-pro-
ficient	siblings	(Dollé	et	al.,	2011),	indicating	that	the	oral	dose	of	ra-





this	 age,	Ercc1∆/−	progeroid	mice	 still	 show	minor	 indications	 (e.g.,	
growth	retardation)	of	DNA	damage	accumulation	(de	Waard	et	al.,	
2010;	Dollé	et	al.,	2011;	Vermeij,	Hoeijmakers,	et	al.,	2016).	We	first	
focused on females as in previous studies they showed the biggest 
improvement	 following	 rapamycin	 treatment	 (Garratt	 et	 al.,	 2016;	
Miller	et	al.,	2014).	We	monitored	body	weight	and	food	intake	to	ex-






2016).	However,	when	monitoring	survival	of	Ercc1∆/− mice fed ad 
libitum	 control	or	 rapamycin	diet,	we	failed	 to	 find	any	 increase	 in	
median	or	maximum	life	span	(Figure	1d).
One	 possible	 explanation	 is	 that	 rapamycin	was	 administered	
too	 early	 in	 development.	Moreover,	 rapamycin	 appears	 to	work	
predominantly	later	in	life	(Harrison	et	al.,	2009).	Therefore,	we	re-
peated the study in a second cohort of Ercc1∆/−	females,	now	start-
ing	the	rapamycin	diet	at	8	weeks	of	age,	that	is,	early	adulthood.	At	
this	age,	Ercc1∆/− progeroid mice have developed first clear symp-
toms	of	 aging	 (de	Waard	et	 al.,	 2010;	Dollé	 et	 al.,	 2011;	Vermeij,	




nutritional	 supplementation	 of	 14	 ppm	 rapamycin	 on	 mTORC1	
activity in Ercc1∆/− mice by measuring phosphorylation of ribo-
somal	protein	S6	(at	Serine240	and	Serine244),	and	we	took	dietary	
restriction along as a positive control. Rapamycin indeed reduced 
S6S240/244	phosphorylation	by	about	one-third	analyzed	after	three	
weeks	 compared	 to	mock-treated	 controls	 (Figure	 1e	 and	 Figure	
S1).	We	 did	 not	 notice	 significant	 suppression	 of	 body	weight	 or	
food	intake,	in	contrast	with	DR	(Figure	1f,g,	Figure	S2a–c	and	Table	
S1).	While	 30%	DR	 confirmed	 the	 impressive	 life	 span	 extension	
in a new cohort of Ercc1∆/−	 females,	 rapamycin	 failed	 to	 improve	
median	 or	maximal	 life	 span	 (Figure	 1h).	 Ercc1∆/− mice subjected 









we also included male mice to control for potential gender specific 
effects.	 The	 treatment	with	 rapamycin	 reduced	 body	weight,	 in	 a	
dose-dependent	manner	 (Figure	2a,b,e,f	and	Table	S1),	without	af-
fecting	 food	 intake	 (Figure	 2c,g).	However,	 altered	 doses	 of	 rapa-
mycin	 still	 failed	 to	 extend	 (or	 shorten)	 life	 span	 of	 Ercc1∆/− mice 
(Figure	2d,h),	in	line	with	the	14	ppm	treatment.
2.2  |  Effect of rapamycin on parameters of 
healthspan of Ercc1Δ/− mice
Although	rapamycin	appears	inert	in	extending	life	span	it	might	still	
alleviate some of the features of organ functional decline that were 
previously	rescued	by	DR	(Vermeij,	Dollé,	et	al.,	2016).	Rapamycin,	
like	 DR,	 is	 known	 for	 reducing	 cancer	 (Anisimov	 et	 al.,	 2010;	
Blagosklonny,	2012;	Livi	et	al.,	2013;	Rao	et	al.,	2004).	Neoplastic	le-
sions were not observed in any of the moribund and cross-sectional 
animals	fed	rapamycin	or	control	diet,	consistent	with	the	previous	
observation of absent neoplasia in short-lived Ercc1∆/−	mice	 (Dollé	
et	al.,	2011).	Additionally,	no	obvious	macroscopical	differences	 in	
major organs and tissues were noted between rapamycin-fed and 
control-treated animals.
The	 liver	exhibits	 substantial	 age-related	pathology	 in	Ercc1∆/− 
mice	 (Dollé	et	al.,	2011;	Gregg	et	al.,	2012;	Selfridge	et	al.,	2001),	
in	particular	hepatocyte	polyploidization	that	possibly	follows	from	




by rapamycin in Ercc1∆/−	liver	extracts.	Six	animals	per	group	were	used	treated	from	8	to	11	weeks	of	age.	Mean	±	SD	and	individual	
datapoints are indicated. *p	<	0.05.	f–h,	Body	weight	(f)	and	AUC	thereof	(for	details,	see	Table	S1)	(g)	(both	mean	±	SD)	and	survival	curves	
(h)	of	a	second	cohort	of	female	Ercc1∆/−	mice	fed	14	ppm	rapamycin	diet	(green)	or	30%	dietary	restriction	(DR;	red)	from	8	weeks	of	age	




(e) (f) (g) (h)
(b) (c) (d)








examined its impact on endothelial function by studying aortic en-
dothelium-dependent	 relaxation	 to	 acetylcholine	 (ACh)	 in	 organ	
bath	 setups.	 Unlike	 DR,	 which	 is	 consistently	 protective,	 rapa-
mycin has been reported as toxic in human aged arteries and in 
rodent	models,	but	paradoxically	also	protective	 in	blood	vessels	
in	healthy	aging	mice	(Habib	et	al.,	2014;	Harari	et	al.,	2018;	Jabs	
et	 al.,	 2008;	 Kim	 et	 al.,	 2010;	 Lesniewski	 et	 al.,	 2017).	 Contrary	
to	 previously	 reported	 protection	 by	 DR	 (Vermeij,	 Dollé,	 et	 al.,	
2016;	Wu	 et	 al.,	 2017),	 endothelium-dependent	 responses	 were	
decreased by rapamycin in both Ercc1∆/−	and	WT	mice,	supporting	
the	toxic	effects	that	were	reported,	among	others,	in	human	aged	
arteries	(Figure	S3a,b).
Ercc1∆/− mice develop progressive neurological and neurode-
generative	changes	 (Borgesius	et	al.,	2011;	de	Waard	et	al.,	2010;	
Jaarsma	et	al.,	2013),	which	are	strongly	attenuated	by	DR	(Vermeij,	
Dollé,	 et	 al.,	 2016).	Next,	we	 investigated	 the	 effect	 of	 high-dose	
rapamycin	(42	ppm)	on	neurological	and	neurodegenerative	changes	
F I G U R E  2 Altering	dosage	of	rapamycin	does	not	extend	life	span	of	Ercc1∆/−	mouse	mutants	in	both	genders.	Body	weight	means	
per	week	(a,	e),	body	weight	AUC	(for	details	see	Table	S1)	(b,	f),	food	intake	(c,	g),	and	survival	(d,	h)	curves	of	female	(a–d)	and	male	(e–h)	
Ercc1∆/− mice fed ad libitum	control	AIN93G	diet	(black	dotted	lines;	Control),	supplemented	with	empty	microcapsules	(gray;	Control-M),	
4.7	ppm	rapamycin	(pink),	or	42	ppm	rapamycin	(blue)	from	8	weeks	of	age	(arrowhead).	p values of the log-rank survival test are indicated 
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F I G U R E  3 Rapamycin	does	not	prevent	nervous	system	abnormalities	in	Ercc1∆/−	mice.	a,	Onset	of	the	neurological	abnormality	tremors	
with age in ad libitum	control	AIN93G	diet	supplemented	with	empty	microcapsules	(gray;	Control-M)	and	42	ppm	rapamycin	(blue)	fed	
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in Ercc1∆/−	mice.	 This	 cohort	 was	 examined	weekly	 for	 the	 onset	
of tremors and loss of motor performance on an accelerating ro-
tarod; two neurological symptoms that develop in a predictable way 
in Ercc1∆/−	mice	 (de	Waard	 et	 al.,	 2010)	 and	 that	 are	 dramatically	
delayed	or	attenuated	in	DR-treated	animals	(Vermeij,	Dollé,	et	al.,	
2016).	Rapamycin	did	not	alter	the	onset	of	tremors	(Figure	3a),	nor	









Using	 immunoblots,	 we	 next	 examined	 proxies	 of	 neuronal	
injury	 using	GFAP,	 a	marker	 that	 correlates	with	 reactive	 astro-
cytosis,	 and	 NeuN,	 a	 general	 neuronal	 marker	 (Borgesius	 et	 al.,	
2011;	 de	 Waard	 et	 al.,	 2010).	 Rapamycin-	 and	 control-treated	
Ercc1∆/−	 mice	 expressed	 similar	 levels	 of	 GFAP	 and	 NeuN,	 sug-
gestive	 of	 equal	 levels	 of	 neuronal	 injury	 (Figure	 3d	 and	 Figure	




rapamycin	 treatment	 in	 the	 neocortex	 (Figure	 3g,h,	 arrows).	 In	
summary,	our	results	show	that	rapamycin	has	no	effect	on	behav-




treatment in attenuating nervous system abnormalities in Ercc1∆/− 
mice,	we	examined	 the	 cerebellum	 for	GFAP	 staining	 (Figure	3i)	






2009),	 and	 their	 degeneration	 may	 underlie	 motor	 dysfunction	
in	 progeria	 patients	 and	 mouse	 models	 (Jaarsma	 et	 al.,	 2013;	
Weidenheim	et	al.,	2009).	Immunostaining	for	calbindin	to	selec-
tively outline Purkinje cells revealed multiple gaps in the staining 
of the molecular layer of control and rapamycin-treated Ercc1∆/− 
mice,	 indicative	of	Purkinje	cell	 loss,	while	 in	DR	cerebellum	the	
PCs	appeared	more	preserved	 (Figure	3j,	 asterisks).	 Importantly,	
quantitative	 analysis	 of	 Purkinje	 cells	 using	 a	 stereological	 ap-
proach confirmed that rapamycin-fed Ercc1∆/− mice showed a 





2.3  |  Genetically altering mTOR activity does not 
influence life span of Ercc1∆/− mice
The	 lack	of	 effect	 of	 rapamycin	 indicates	 that	 inhibition	of	mTOR	
signaling does not interfere with life span of Ercc1∆/− mice and that 
mTOR	 inhibition	 does	 not	 mediate	 the	 beneficial	 effect	 of	 DR	 in	
these	mice.	However,	it	is	not	excluded	that	in	our	DNA	repair	mu-
tant mice rapamycin exerts additional negative effects other than 
via	 inhibiting	 mTOR	 activity.	 Therefore,	 we	 investigated	 modula-
tion	of	mTOR	activity	 bidirectionally	 via	 a	 genetic	 approach	using	
Rheb+/−	mice	(Goorden	et	al.,	2011)	and	Tsc1+/−	mice	(Wilson	et	al.,	
2005),	 two	 key	 upstream	 regulators	 of	mTORC1:	 RHEB	 is	 a	 small	
Ras-related	GTPase	that	stimulates	mTORC1	activity,	while	TSC1	is	
a	GTPase-activating	protein	that	converts	RHEB	to	its	GDP-bound	
state	 thereby	 inactivating	mTORC1	activity	 (Liu	&	Sabatini,	2020).	
As	both	mouse	mutations	are	homozygously	lethal,	heterozygously	
mutating Rheb or Tsc1 has been shown to lower protein expres-
sion,	 and	 respectively	 suppress	 or	 enhance	 mTORC1	 activity	 by	
one	third	(Goorden	et	al.,	2011;	Wesseling	et	al.,	2017).	Both	these	
mouse	models,	which	were	studied	previously	 in	 light	of	neuronal	
development	but	never	 life	 span,	were	crossed	with	Ercc1∆/− mice 
in	 the	 same	 F1	C57BL6J/FVB	 hybrid	 background.	 In	 addition,	we	




Consistent	 with	 the	 rapamycin	 treatment,	 reduced	 mTORC1	
activity resulting from deletion of one Rheb allele did not alter the 
time	of	onset	of	neurological	deficits	 (tremors	and	 imbalance),	 the	
time	of	onset	of	kyphosis,	and	life	span	in	Ercc1∆/−	mice	(Figure	4a-d;	
green	 lines)	nor	 in	Xpg−/−	mice	 (Figure	4e-h;	green	 lines).	 Similarly,	




activity	 genetically,	 our	 DNA	 repair-deficient	 prematurely	 aging	
mice appear insensitive to the healthspan and life span-modulating 
activity	of	mTOR	inhibition.
2.4  |  Effect of rapamycin on age-related 
transcription stress
To	 obtain	 a	 more	 mechanistic	 understanding	 of	 the	 large	 dif-
ference	 in	 effects	 of	 rapamycin	 treatment	 vs	DR	on	 survival	 of	
Ercc1∆/−	mice,	we	next	examined	the	effect	of	14	ppm	rapamycin	
on the liver full genome transcriptome of Ercc1∆/−	mice	versus	WT	
controls	and	compared	it	to	simultaneously	re-analyzed	changes	
induced	by	DR.	Unbiased	principal	component	analysis	revealed	
high similarity between Ercc1∆/− mice fed ad libitum control 
(Control)	or	rapamycin	 (Rapa	14	ppm)	diet	 (Figure	5a	and	Figure	
S6a),	 whereas	 Ercc1∆/−	 mice	 given	 a	 restricted	 diet	 (DR	 30%)	
were	clearly	 separated,	 like	WT	mice	 fed	ad libitum control diet 
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(WT-Control)	 or	 subjected	 to	 30%	 dietary	 restriction	 (WT-DR)	
(Figure	5a	and	(Vermeij,	Dollé,	et	al.,	2016).	As	microarray	expres-
sion revealed no significant gene expression changes between 
Ercc1∆/−	mice	on	rapamycin	or	control	diet	(using	FDR	<	0.05	with	
FC	≥	|1.5|),	consistent	with	PCA	analysis,	we	decided	to	compare	
both	 groups	 to	WT’s	 fed	 control	 diet,	 again	 showing	 consistent	




differing	upon	DR	 treatment:	 for	 example,	CDKN1A	expression	








likelihood that a gene suffers from a lesion blocking transcription is 
directly	proportional	to	its	length,	thus	leading	to	a	genome-wide	
decline	 of	 expression	 of	 primarily	 larger	 genes	 (Nakazawa	 et	 al.,	
F I G U R E  4 Genetically	altering	mTOR	activity	does	not	influence	life	span	of	Ercc1∆/−	mice.	a–c,	Onset	of	neurological	abnormalities,	
tremors	(a)	and	imbalance	(b),	and	kyphosis	(c)	with	age	in	Ad libitum fed Ercc1∆/−Rheb+/−	(green	lines;	reduced	mTOR)	and	Ercc1∆/−Tsc+/− 
(orange	lines;	increased	mTOR)	mutant	mice	and	littermate	control	Ercc1∆/−	mice	(black	dotted	lines).	d,	Survival	of	Ercc1∆/−Rheb+/−	(green	
lines;	reduced	mTOR)	and	Ercc1∆/−Tsc+/−	(orange	lines;	increased	mTOR)	mutant	mice	and	littermate	control	Ercc1∆/−	mice	(black	dotted	
lines).	n	=	9	animals	per	group	for	Rheb+/− and Tsc+/− mutants and 20 for Ercc1∆/−	controls.	e–h,	survival	curves	(e)	and	onset	of	neurological	
abnormalities,	tremors	(f)	and	imbalance	(g),	and	kyphosis	(h)	with	age	in	Ad libitum fed Xpg−/−Rheb+/−	(green	lines;	reduced	mTOR)	and	
Xpg−/−Tsc+/−	(orange	lines;	increased	mTOR)	mutant	mice	and	littermate	control	Xpg−/−	mice	(black	dotted	lines).	n = 10 animals per group 
for Rheb+/− and Tsc+/− mutants and 21 for Xpg−/− controls. p values of the log-rank test are indicated and refer to the comparison of 
each	intervention	group	to	its	own	control.	When	stratified	for	gender,	log-rank	survival	estimate	p	values	were	0.0843	and	0.1983	for	
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2020;	Vermeij,	Dollé,	et	al.,	2016).	The	distribution	of	expression	
changes	 from	 large	 and	 small	 genes,	 as	 inferred	 from,	 for	 exam-
ple,	 liver	 transcriptomic	 data,	 has	 previously	 been	 identified	 as	
indicator	 of	 transcription	 stress,	 increasing	 with	 age	 in	 rodents	
and	humans,	 elevated	by	DNA	 repair	deficiency,	but	 largely	 alle-
viated	by	DR	 (Milanese	et	 al.,	 2019;	Vermeij,	Dollé,	 et	 al.,	 2016).	
Compared	 to	WT	 animals,	Ercc1∆/− mice showed a highly signifi-
cant bias for large genes to be underrepresented in the category 
of genes showing increased expression and overrepresented in the 
class	of	genes	with	reduced	expression	(Figure	5b,c;	gray	solid	ver-
sus	black	dashed	lines;	see	arrows;	and	Table	S3).	While	this	shift	
in expression of large versus small genes was strongly attenuated 
by	DR	 (Figure	5b,c;	 red	 lines	and	Table	S3),	 rapamycin	 treatment	
failed to alleviate this parameter of age-related transcription stress 
in Ercc1∆/−	liver	(Figure	5b,	c;	green	lines	and	Table	S3).
Together,	these	data	indicate	that	rapamycin	has	a	minimal	effect	
on the liver transcriptional landscape and does not induce transcrip-
tion	changes	triggered	by	DR	that	may	underlie	its	beneficial	effects	






The	 quest	 for	 DR	 mimetics	 has	 promoted	 rapamycin	 as	 a	 strong	
candidate	 drug	 for	 anti-aging	 interventions	 (Blagosklonny,	 2019;	




Dollé,	et	al.,	2016).	Unlike	DR,	 rapamycin	 failed	to	 improve	 impor-
tant	parameters	of	healthspan:	 liver,	 vascular	 and	nervous	 system	
pathology,	 and	neurological	 deficits.	We	 tested	 rapamycin	 in	mul-
tiple	 cohorts,	 consistently	 finding	no	effect	on	 survival	 independ-




affecting	food	intake,	 indicating	that	rapamycin	in	Ercc1∆/− mice at 
least	in	part	reproduces	a	main	biological	effect	found	in	WT	mice	





F I G U R E  5 Rapamycin	does	not	prevent	transcription	stress	in	Ercc1∆/−	liver.	a,	Principal	component	analysis	(PCA)	of	full	genome	liver	









Control	and	Rapa	14	ppm	mice.	Average	gene	lengths	and	p	values	of	comparisons	are	indicated	in	Table	S3.	n = 4–5 animals per group
(a) (b)
(c)
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Xpg−/−	mice,	distinct	progeroid	mouse	models	carrying	deficiencies	
in	different	DNA	repair	genes,	ruling	out	that	inability	of	rapamycin	
to extend life span is somehow Ercc1-specific	(Figure	6).	As	all	inter-
ventions,	via	different	dosages	of	rapamycin	and	by	genetic	means,	
did	not	yield	health-	or	life	span	benefits,	 it	would	be	unlikely	that	
negative and positive effects would cancel out under all these condi-












different	 mechanisms,	 again	 questioning	 the	 extent	 to	 which	
rapamycin	can	be	 regarded	as	DR	mimetic	 (Garratt	et	al.,	2016;	
Thompson	 et	 al.,	 2018;	 Tyshkovskiy	 et	 al.,	 2019;	 Unnikrishnan	
et	al.,	2020).
Rapamycin may extend survival mainly via acting only on a nar-
row	subset	of	aging	traits,	in	particular	altered	immune	function	and	
suppression	 of	 cancer	 (Christy	 et	 al.,	 2015;	 Ehninger	 et	 al.,	 2014;	
Hasty	et	al.,	2014;	Livi	et	al.,	2013).	A	scenario	where	the	anti-ag-
ing effect primarily results from its anti-cancer effect would match 





mice	with	 short	 telomeres	 (Ferrara-Romeo	et	 al.,	 2020).	Although	
the Ercc1∆/−	mice	age	accelerated,	they	and	related	progeria	patients	
do	not	have	shortened	telomeres	(Zhu	et	al.,	2003).	Rapamycin	has	
been	 found	 to	 extend	 life	 span	 in	 progeroid	 Lamin	 A/C-deficient	
mice	 that	 models	 Hutchinson–Gilford	 progeria	 syndrome	 (HGPS)	
(Kawakami	 et	 al.,	 2019;	 Ramos	 et	 al.,	 2012).	 These	 mice	 display	
overall	 increased	 mTORC1	 activity,	 and	 the	 beneficial	 effect	 has	





Our	 transcriptome	 analysis	 reveals	 that	 rapamycin	 and	 DR	
have effects on the Ercc1∆/−	 liver	transcriptome	that	are	qualita-
tively	and	quantitatively	very	different,	with	rapamycin-fed	mice	
clustering with the ad libitum fed Ercc1∆/−	controls.	These	data	are	
consistent	 with	 transcriptome	 analyses	 of	 liver	 from	 WT	 mice,	





work via mechanisms that cannot be easily altered in the Ercc1∆/− 






by	DR	and	 in	 long-lived	GHR-KO	dwarf	mice	 (Schumacher	et	al.,	
2008;	Vermeij,	Dollé,	et	al.,	2016).	Intriguingly,	rapamycin	also	fails	
in	increasing	life	span	in	GHR-KO	mice,	but	rather	shortens	their	
life	 span	 (Fang	 et	 al.,	 2018).	 This	 reduced	 longevity	 of	 GHR-KO	
mice has been linked to potential effects of rapamycin such as 
disrupted	glucose	and	lipid	metabolism	homeostasis,	and	reduced	
immune	function	(Fang	et	al.,	2018).	The	data	of	the	GHR-KO	mice	
indicate	 that	 the	 context	 of	 lower	 GH	 signaling	 as	 observed	 in	
our Ercc1∆/− and Xpg−/− mice may mask the beneficial effects of 
rapamycin.
The	central	remaining	question	is	as	follows:	How	does	DR	delay	
aging in Ercc1∆/−	mice?	 Several	 interventions	 in	DNA	 repair-defi-
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van	Beek	et	al.,	2017;	Vermeij,	Dollé,	et	al.,	2016;	Wu	et	al.,	2017).	









reactive	 species,	 reducing	DNA	damage	 and	 transcription	 stress,	
which are factors underrepresented in current anti-aging studies.
Interestingly,	 rapamycin-mediated	 inhibition	 of	 mTORC1	 has	




anisms,	 enhancing	 DNA	 damage	 response	 signaling	 is	 expected	
to	fail	in	extending	life	span	in	these	mice.	This	idea	is	fully	in	line	
with our findings; especially the absence of an effect by rapamycin 




Dollé,	 et	 al.,	 2016).	 Hence,	 an	 important	 anti-aging	 effect	 of	 DR	
may	be	triggering	the	protective	“survival	response”,	which	includes	
boosting anti-oxidant defenses and metabolic redesign thereby 
reducing	the	DNA	damage	 load,	consistent	with	the	alleviation	of	
genome-wide	 transcription	 stress	 by	 DR.	 Since	 repair-deficient	






4  |  E XPERIMENTAL PROCEDURES
4.1  |  Ethics statement
All	 of	 the	 animals	 used	 in	 the	 experimental	 procedures	were	 in	
accordance	 with	 the	 Principles	 of	 Laboratory	 Animal	 Care	 and	
with	 the	 guidelines	 approved	 by	 the	 Animal	 Ethical	 Committee	
of	 the	National	 Institute	 for	 Public	Health	 and	 the	 Environment	
(DEC	 no.	 200900263,	 201100026,	 and	 2016-0047-011)	 or	
Erasmus	MC	 (DEC	 no.	 139-12-12	 and	 139-12-13)	 in	 full	 accord-
ance	with	European	 legislation	 (Recommendation	2007-526-EC).	
Animals	were	maintained	 in	a	controlled	environment	 (20–22°C,	
12	 h	 light:12	 h	 dark	 cycle)	 and	were	 housed	 in	 individual	 venti-
lated	cages	under	specific	pathogen-free	conditions.	Animals	were	
group	housed	at	 the	RIVM	 location	when	possible	and	 individu-
ally	housed	at	the	EMC	location.	Food	and	water	were	offered	ad 
libitum	unless	otherwise	stated.	All	efforts	were	made	to	amelio-
rate the suffering of the animals.
4.2  |  Mouse models
The	 generation	 and	 characterization	 of	 Ercc1∆/+ and Ercc1+/− mice 
have	been	previously	described	 (Weeda	et	al.,	1997).	Ercc1∆/− mice 





Xpg−/−	 mice	 have	 been	 characterized	 previously	 (Barnhoorn	 et	 al.,	
2014)	and	were	generated	by	crossing	Xpg+/−	(in	a	pure	C57BL6J	back-
ground)	with	Xpg+/−	mice	 (in	a	pure	FVB	background).	Rheb+/− mice 
and Tsc+/−	mice	have	both	been	described	previously	(Goorden	et	al.,	
2011)	 and	 were	 of	 a	 pure	 C57BL6J	 background.	 These	 heterozy-
gous lines were first crossed with Ercc1∆/+,	Ercc1+/−,	and	Xpg+/− mice 
(all	 in	pure	C57BL6J	backgrounds)	prior	to	the	generation	of	F1	hy-
brid Ercc1∆/− and Xpg−/−	mice.	Hence,	all	animals	used	in	the	studies	
described	 here	were	 of	 the	 same	 genetic	 F1	 C57BL6J/FVB	 hybrid	
background.	Typical	unfavorable	characteristics,	such	as	blindness	in	




lection bias. Mice were clinically diagnosed daily in a blinded manner 
and,	weighed,	visually	inspected	weekly,	and	where	indicated	scored	
in a blinded fashion for gross morphological and motor abnormalities. 
Since	 the	Ercc1∆/− and Xpg−/−	mice	were	smaller,	 food	was	adminis-
tered	within	the	cages	and	water	bottles	with	long	nozzles	were	used	
from around two weeks of age.
4.3  |  Dietary treatment with rapamycin
All	animals	were	bred	and	maintained	on	AIN93G	synthetic	pellets	
(Research	Diet	 Services	 B.V.;	 gross	 energy	 content	 4.9	 kcal/g	 dry	
mass,	digestible	energy	3.97	kcal/g,	using	2.3	g/kg	choline	chloride	
instead	of	choline	bitartrate).	Microencapsulated	rapamycin	(eRapa)	
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(2.1	 g/day),	 when	 animals	 reached	 almost	 maximum	 body	 weight	
and	development	was	completed.	Dietary	restriction	was	increased	
weekly	by	10%,	until	it	reached	30%	dietary	restriction	(1.6	g/day)	
from	9	weeks	 of	 age	 onward.	 Food	was	 given	 to	 the	 animals	 just	
before	the	start	of	the	dark	(active)	period	to	avoid	alteration	of	the	
biological clock.
4.4  |  Phenotype scoring
The	mice	were	weighed	and	visually	 inspected	weekly,	and	were	
scored in a blinded manner by three experienced research techni-
cians	 for	 the	 onset	 of	 various	 phenotypical	 parameters.	Whole-
body tremor was scored if mice were trembling for a combined 
total	of	at	least	10	s	when	put	on	a	flat	surface	for	20	s.	Impaired	
balance was determined by observing the mice walking on a flat 
surface for 20 s. Mice that had difficulties in maintaining an up-
right orientation during this period were scored as having im-
balance. Mice showing an abnormal curvature of the spine were 
scored as having kyphosis.
4.5  |  Behavioral analyses
Rotarod performance was assessed by measuring the average time 
spent	on	an	accelerating	rotarod	(Ugo	Basile).	All	animals	were	given	
four consecutive trials of a maximum of 5 min with inter-trial intervals 
of	1	h.	For	weekly	monitoring,	the	motor	coordination	performance	
was measured with two consecutive trials of a maximum of 5 min.
4.6  |  Immunoblotting
Liver	extracts	were	prepared	by	mechanical	disruption	in	lysis	buffer	









RRID:AB_331682;	 1:500),	 and	 mouse	 anti-β-Actin	 (Sigma	 Aldrich;	
A5441	Lot064M4789V,	RRID:AB_476744;	1:25.000)	were	used	 for	
detection,	semi-quantified	using	the	ImageJ	software	package	(http://
rsb.info.nih.gov/ij/index.html),	 and	 phosphorylated:total	 ratios	 rela-









using	 wet	 transfer.	 Membranes	 were	 blocked	 in	 5%	 BSA	 or	 5%	
milk for an hour at room temperature and incubated overnight at 
4	°C.	Following	primary	antibodies	were	used:	rabbit	anti-pS6	(Ser	
240/244,	 Cell	 Signaling	 Technology;	 5364,	 RRID:AB_10694233;	
1:1000),	 mouse	 anti-S6	 (Santa	 Cruz	 Biotechnology;	 SC-74459,	
RRID:AB_1129205	 1:1000),	 rabbit	 anti-GFAP	 (DAKO;	 Z0334,	
RRID	 AB_10013382;	 1:5000),	 chicken	 anti-Neun	 (Millipore;	
ABN78,	 RRID:AB_10807945;	 1:5000),	 rabbit	 anti-Beclin	 (Cell	
Signaling	Technology;	3738,	RRID:AB_490837;	1:1000),	rabbit	an-
ti-LC3	(Cell	Signaling	Technology;	2775,	RRID:AB_915950;	1:750),	
and	 mouse	 anti-Actin	 (Millipore;	 MAB1501,	 RRID:AB_2223041;	
1:20.000).	 Secondary	 antibodies	 were	 either	 horseradish	 perox-
idase	conjugated	 (HRP;	 Invitrogen;	G-21234,	RRID:AB_2223041;	
1:5000)	 or	 near-infrared-dye	 conjugated	 (IRDye;	 Licor	 Biotech,	
926-32212/926-32213/926-68075/926-68075/926-68072/926-
68073;	1:20.000)	and	were	incubated	for	one	hour	at	room	tem-
perature.	 Antibody	 recognition	 was	 done	 either	 with	 Pierce™	














with 5 μg/ml	PI	 and	250	μg/ml	RNase	and	 samples	were	measured	
using	the	FACS	(FACSCalibur,	Becton	Dickinson).
4.8  |  Histological procedures
Mice	 were	 anaesthetized	 with	 pentobarbital	 and	 perfused	 tran-
scardially	with	 4%	 paraformaldehyde.	 The	 brain	 specimens	were	
carefully	dissected	out,	post-fixed	for	1	h	in	4%	paraformaldehyde,	
cryoprotected,	embedded	in	12%	gelatin,	rapidly	frozen,	and	sec-
tioned at 40 μm	 using	 a	 freezing	microtome	 or	 stored	 at	 −80°C	




RRID	number;	dilution)	used	 in	 this	study	were	as	 follows:	 rabbit	
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anti-GFAP	 (DAKO;	 Z0334,	 AB_10013382;	 1:8000);	 mouse	 anti-
NeuN	(Millipore;	MAB377,	AB_2298772;	1:1,000);	rabbit	anti-P53	
(Leica;	 NCL-p53-CMP5,	 AB_2744683;	 1:1000);	 rabbit	 anti-Cal-
bindin	 (Swant;	CB-38a,	AB_2314070;	1:20,000);	mouse	 anti-Cal-
bindin	 (Sigma	Aldrich;	 C9848,	 AB_2313712;	 1:20,000);	 and	 goat	
anti-FOXP2	 (Santa	 Cruz	 Biotechnology;	 sc21069,	 AB_2107124;	
1:1000).	 Alexa488-,	 Cy3-,	 and	 Cy5-conjugated	 secondary	 anti-





4.9  |  Quantitative analysis of Purkinje cells
Quantification	 of	 Purkinje	 cells	 was	 done	 using	 the	 Optical	
Fractionator	tool	of	the	StereoInvestigator	software	package	(MBF	
Bioscience),	 integrated	 in	 a	 Zeiss	 LSM700	 confocal	 microscope	
setup. Cerebellar tissue was coronally cut serially into 40 μm sec-
tions.	Every	8th	section	was	double-immunostained	for	calbindin	
(Swant;	 CB-38a,	 RRID:	 AB_2314070;	 1:20,000/Sigma	 Aldrich;	










nucleus in a counting box of 150 * 150 * 20 μm. Cells whose nu-
cleus crossed either the upper surface or the lower or right sides 
of	the	counting	frame	were	not	counted,	according	to	the	optical	
fractionator	counting	rules.	To	obtain	an	estimate	of	the	total	num-
ber	 of	 Purkinje	 cells,	we	divided	 the	 counted	number	 of	 cells	 by	
the relative fraction of tissue counted using the following formula





4.10  |  Ex vivo vascular function
The	responses	of	isolated	aortic	tissue	were	ex vivo measured in small-
wire	myograph	organ	baths	containing	oxygenated	Krebs–Henseleit	
buffer	at	37°C.	After	preconstriction	with	30	nM	U46619,	 relaxa-
tion concentration–response curves to acetylcholine followed by 
0.1	mM	sodium	nitroprusside,	a	nitric	oxide	donor,	were	constructed	
(Durik	 et	 al.,	 2012).	 To	 specifically	 reveal	 endothelium-dependent	
responses,	which	in	Ercc1∆/−	and	their	WT	littermates	almost	exclu-
sively	consist	of	nitric	oxide	signaling,	acetylcholine	responses	were	
corrected for the response to sodium nitroprusside.
4.11  |  Microarray-based transcription 
stress analysis
Total	 RNA	was	 extracted	 using	QIAzol	 lysis	 Reagent	 from	mouse	
liver.	 For	 increased	 purity,	 miRNAeasy	 Mini	 Kits	 (QIAGEN)	 were	
used.	Addition	of	wash	buffers	RPE	and	RWT	(QIAGEN)	was	done	
mechanically	by	using	the	QIAcube	(QIAGEN)	via	the	miRNeasy	pro-






Affymetrix	 HT	 MG-430	 PM	 Array	 Plates	 was	 performed	 at	 the	
Microarray	Department	of	the	University	of	Amsterdam	according	
to	 Affymetrix	 protocols.	 Quality	 control	 and	 normalization	 were	
performed using the pipeline at www.array analy sis.org.
The	linear	model	from	Limma	implemented	in	R	was	used	to	iden-
tify	the	DEGs.	Pairwise	comparisons	for	each	genotype	between	ad 
libitum and dietary restriction samples were applied to calculate the 




Pathway enrichment analysis was conducted via overrepresenta-
tion	analysis	 (ORA).	ORA	was	performed	 in	 the	 interactive	pathway	
analysis	(IPA)	of	complex	genomics	data	software	(Ingenuity	Systems,	
Qiagen)	 by	 employing	 a	 pre-filtered	 list	 of	 differentially	 expressed	
genes.	The	overrepresented	canonical	pathways	were	generated	based	
on	information	in	the	Ingenuity	Pathways	Knowledge	Base.	A	pathway	
was selected as deregulated when the p	value	in	the	Fisher	test	was	
lower	 than	 0.01.	 Additionally,	 IPA	 transcription	 factor	 (TF)	 analysis	
was performed to identify the cascade of upstream transcriptional 





and also compares their direction of change to what is expected from 
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and	activation	z-score).	The	overlap	p value labels upstream regulators 
based on significant overlap between dataset genes and known tar-
gets	regulated	by	a	TF.	The	activation	z-score	is	used	to	infer	the	likely	
activation states of upstream regulators based on comparison with a 









probe	sets	 in	 the	original	microarray).	Finally,	 a	 relative	 frequency	
(kernel	density)	plot	of	gene	length	and	probability	density	for	DEG	
in each comparison was drawn using the density function imple-
mented	 in	 R.	 Kernel	 density	 estimates	 are	 related	 to	 histograms,	
but with the possibility to smooth and continuity by using a kernel 
function.	The	y-axis	represents	the	density	probability	for	a	specific	
range of values in the x-axis.
All	data	files	have	been	submitted	to	the	NCBI	gene	expression	
omnibus	(GEO)	under	accession	number	GSE149029.
4.12  |  Statistical analysis
All	data	with	error	bars	are	presented	as	mean	±	standard	deviation	
(SD),	 and	 the	 individual	datapoints	 (dots)	 are	presented	 in	 the	bar	
graphs.	All	analyses	were	performed	using	GraphPad	Prism	version	
8.4.2	(GraphPad	Software,	La	Jolla	California	USA)	and	R	software.	











the gene length transcription stress analysis were determined using 
the	Wilcoxon–Mann–Whitney	(WMW)	test.
Weekly	body	weights	from	the	age	of	intervention-start	through	
the maximum age at which all groups of the respective experiment still 
had	≥80%	survival	were	included,	excluding	the	weights	of	the	animals	
that	died	during	that	period.	Subsequently,	all	the	body	weights	after	
the start of the intervention were log10-transformed,	had	the	log10 val-
ues	at	the	start	of	the	intervention	subtracted	from	them,	and	then,	for	
convenience	(this	being	no	more	than	a	normalization	without	any	ef-
fect	on	the	statistical	tests),	had	the	lowest	log10-baseline weight of the 
entire	dataset	subtracted	from	them.	Then,	the	area	under	the	curve	
(AUC)	was	determined	by	 the	 trapezoid	 rule	 for	 the	entire	 selected	




Statistics	 for	 life	 span	 and	 onset	 of	 phenotypes	 were	 per-
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